IMWG consensus on risk stratification in multiple myeloma
Standard
IMWG consensus on risk stratification in multiple myeloma. / Chng, W J; Dispenzieri, A; Chim, C-S; Fonseca, R; Goldschmidt, H; Lentzsch, S; Munshi, N; Palumbo, A; Miguel, J S; Sonneveld, P; Cavo, M; Usmani, S; Durie, B G M; Avet-Loiseau, H; International Myeloma Working Group.
in: LEUKEMIA, Jahrgang 28, Nr. 2, 01.02.2014, S. 269-77.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - IMWG consensus on risk stratification in multiple myeloma
AU - Chng, W J
AU - Dispenzieri, A
AU - Chim, C-S
AU - Fonseca, R
AU - Goldschmidt, H
AU - Lentzsch, S
AU - Munshi, N
AU - Palumbo, A
AU - Miguel, J S
AU - Sonneveld, P
AU - Cavo, M
AU - Usmani, S
AU - Durie, B G M
AU - Avet-Loiseau, H
AU - International Myeloma Working Group
AU - Kröger, Nicolaus-Martin
PY - 2014/2/1
Y1 - 2014/2/1
N2 - Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies.
AB - Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies.
KW - Consensus Development Conferences as Topic
KW - Humans
KW - Multiple Myeloma
KW - Prognosis
U2 - 10.1038/leu.2013.247
DO - 10.1038/leu.2013.247
M3 - SCORING: Journal article
C2 - 23974982
VL - 28
SP - 269
EP - 277
JO - LEUKEMIA
JF - LEUKEMIA
SN - 0887-6924
IS - 2
ER -